Matrix metalloproteinases in ureteropelvic junction obstruction.

BACKGROUND Management of ureteropelvic junction obstruction (UPJO) remains controversial. The aim of the present study was to measure the levels of matrix metalloproteinases (MMPs) in UPJO patients who were planned to undergo surgery and thus clarify if MMPs levels could serve as potential biomarkers of surgical obstruction in UPJO. METHODS Serum samples of infants with UPJO diagnosis were compared to serum samples of healthy age-matched controls. MMP2 and MMP9 were quantified using enzyme-linked immunosorbent assay (ELISA). RESULTS A total of 17 infants with UPJO diagnosis, and median age 1.5 months, were prospectively recruited. MMP9 levels were significantly decreased in the serum samples of UPJO infants compared to controls (p =0.037). Also MMP2 values were higher in UPJO infants compared to controls, but the difference was not statistically significant (p =0.206). CONCLUSIONS This study found decreased concentrations of MMP9 in infants with obstructive hydronephrosis. However, the results should be tested in larger population samples and even be evaluated simultaneously with urine samples in order to delineate the ability of MMPs to serve as obstruction biomarkers. HIPPOKRATIA 2017, 21(3): 136-139.

[1]  Lixin Liu,et al.  Matrix metalloproteinase 9-dependent Notch signaling contributes to kidney fibrosis through peritubular endothelial–mesenchymal transition , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  K. Meldrum,et al.  Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. , 2017, American journal of physiology. Renal physiology.

[3]  W. Nahas,et al.  MMP9 overexpression is associated with good surgical outcome in children with UPJO: Preliminary results , 2016, BMC Urology.

[4]  M. Jougasaki,et al.  Matrix Metalloproteinases in Non-Neoplastic Disorders , 2016, International journal of molecular sciences.

[5]  S. Alexander,et al.  Matrix metalloproteinase 9 induces endothelial-mesenchymal transition via Notch activation in human kidney glomerular endothelial cells , 2016, BMC Cell Biology.

[6]  Zhanzheng Zhao,et al.  Urinary Emmprin, matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 as potential biomarkers in children with ureteropelvic junction narrowing on conservative treatment , 2015, Nephrology.

[7]  F. Farrokhyar,et al.  Evaluating practice patterns in postnatal management of antenatal hydronephrosis: a national survey of Canadian pediatric urologists and nephrologists. , 2014, Urology.

[8]  M. Karsdal,et al.  The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? , 2014, Fibrogenesis & tissue repair.

[9]  S. Alexander,et al.  Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage , 2013, Laboratory Investigation.

[10]  Mingxia Xiong,et al.  Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. , 2010, American journal of physiology. Renal physiology.

[11]  C. Schwentner,et al.  Extracellular matrix degradation and reduced neural density in children with intrinsic ureteropelvic junction obstruction. , 2010, Urology.

[12]  Richard S. Lee,et al.  The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. , 2010, Journal of pediatric urology.

[13]  C. Barnewolt,et al.  Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy. , 2010, Journal of pediatric surgery.

[14]  S. Kiley,et al.  Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy , 2010, Pediatric Nephrology.

[15]  B. Bright,et al.  Operative versus nonoperative management of ureteropelvic junction obstruction in children. , 2009, Urology.

[16]  D. Stablein,et al.  Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) * , 2007, Pediatric transplantation.

[17]  A. Parrish,et al.  Role of matrix metalloproteinases in renal pathophysiologies. , 2007, American journal of physiology. Renal physiology.

[18]  S. Fernbach,et al.  Ultrasound grading of hydronephrosis: Introduction to the system used by the society for fetal urology , 1993, Pediatric Radiology.

[19]  A. Michael,et al.  Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. , 1995, The Journal of laboratory and clinical medicine.

[20]  H. van Goor,et al.  Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. , 1995, Journal of the American Society of Nephrology : JASN.